Drug intelligence / Profile preview

Changzhou Univ. TGR5 compound B1 (PMID 37536263)

Development stage: Unknown
Lead developer: Changzhou University
Modality: Small Molecules

Overview

Changzhou Univ. TGR5 compound B1 (PMID 37536263): sourced facts only. name: "Moreover, B1 positively modulate the functional activity of chenodeoxycholic acid (CDCA) in TGR5, indicating that B1 is a TGR5 PAM." [PMID:37536263]; target: "Moreover, B1 positively modulate the functional activity of chenodeoxycholic acid (CDCA) in TGR5, indicating that B1 is a TGR5 PAM." [PMID:37536263]; developer: "School of Pharmacy, Changzhou University, Changzhou 213164, PR China." [PMID:37536263]; modality: "twenty-two novel cholic acid (CA) derivatives were designed and synthesized as potential Takeda G protein-coupled receptor 5 (TGR5) positive allosteric modulators (PAMs) using structure-based drug design (SBDD)" [PMID:37536263]

Targets

GPBAR1

Beyond the preview

Go deeper on Changzhou Univ. TGR5 compound B1 (PMID 37536263).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changzhou Univ. TGR5 compound B1 (PMID 37536263).